Delving into the Latest Updates on Levocarnitine propionate hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

L-Carnitine propionate, Levocarnitine propionate hydrochloride (USAN), Levocarnitine proprionate

+ [10]

Target

PDHK

Action

stimulants

Mechanism

PDHK stimulants(Pyruvate dehydrogenase kinase stimulants)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Peripheral Vascular Diseases

Inactive Indication

Colitis, UlcerativeHeart FailureIntermittent Claudication+ [3]

Originator Organization

Sigma-Tau BV

Active Organization-

Inactive Organization

Sigma-Tau Industrie Farmaceutiche Riunite SpA

Lee's Pharmaceutical Holdings Ltd.

Hefei Zhaofeng Keda Pharmaceutical Co., Ltd. Guangzhou Branch

+ [1]

Drug Highest PhaseApproved

First Approval Date

Italy (01 Jan 1998),

Heart FailurePeripheral Vascular Diseases

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H20ClNO4

InChIKeyKTFMPDDJYRFWQE-DDWIOCJRSA-N

CAS Registry119793-66-7

AbstractAimTo assess the efficacy of the combined administration of myo‐inositol and zinc, a mineral involved in the insulin pathway, in paediatric obesity with insulin resistance on HOMA‐IR, glucose‐insulin metabolism, and lipid profile.Materials and MethodsDouble‐blind, randomized, placebo‐controlled study conducted in North Italy. Fifty‐six patients (10–18 years, Tanner stage ≥3) with obesity and insulin resistance were randomized to myo‐inositol (2000 mg), zinc gluconate (5 mg), and galactooligosaccharides (GOS) from plant‐based origin (1000 mg) (TRT) or placebo (PLC) containing only GOS from plant‐based origin (1000 mg). All patients received an isocaloric diet following the Mediterranean diet style. Data were collected at baseline (V0) and after 3 months (V1). The primary outcome was the insulin resistance index (HOMA‐IR).ResultsFifty out of 56 recruited subjects completed the study. TRT improved HDL cholesterol level compared to PLC (p = 0.05) but not insulin resistance. A stratified post hoc analysis was performed by sex, BMI, and subgroups of adherence to the Mediterranean diet. Subjects were divided for obesity grade, fasting insulin (p = 0.0137) and HOMA‐IR (p = 0.0273) were lower in TRT than in PLC patients, with a greater effect on severe obesity. No adverse events were detected.ConclusionThree months of supplementation with myo‐inositol and zinc were beneficial on lipid profile and in managing obesity complications at least in subjects with severe phenotype. Thus, myo‐inositol and zinc could be used as non‐pharmacological agents. This work suggests a long‐term study with a larger sample size to enrich the findings.

01 Jan 2025·Journal of Veterinary Dentistry

Serum Cortisol and Blood Glucose Concentrations in Anesthetized Dogs Administered Levobupivacaine and Low-Dose Dexmedetomidine for Regional Anesthesia of the Oral Cavity

Article

Author: Seliškar, Alenka ; Pavlica, Matic ; Nemec, Marija ; Kržan, Mojca ; Baš, Anže ; Nemec, Ana ; Kosjek, Tina

The effects on the stress response, postanesthetic sedation, and altered behavior were evaluated following regional anesthesia and dental treatment in 40 dogs. Serum cortisol and blood glucose concentrations were measured following the administration of levobupivacaine (LBUP) 0.5% and dexmedetomidine (DEX) (0.5 µg/kg) or a placebo. The dogs were randomly assigned to 4 groups of 10 dogs each. All dogs received a regional nerve block using LBUP 0.5%. Group 1 (LBUP + DEX IV) also received DEX intravenously (IV); group 2 (LBUP + PLC IV) also received a placebo IV; group 3 (LBUP + DEX IO) also received DEX in one infraorbital (IO) block; and group 4 (LBUP + DEX IA) also received DEX in one inferior alveolar (IA) block. Serum cortisol and blood glucose concentrations were determined before the administration of oral blocks and at the end of the procedure. Sedation and behavior scores were assessed before premedication and hourly for 6 h after the end of anesthesia. Cortisol concentration did not change in any group at either evaluation time. The glucose concentration was higher ( P < .05) only in the LBUP + DEX IA group at the end of the procedure. The sedation score was higher until the end of the observation period only in the LBUP + DEX IV and LBUP + PLC IV groups. No change in behavior score was observed in any of the groups. The reduction of perioperative stress response in all groups was due to the use of LBUP and not DEX.

01 Dec 2024·Psychiatry Research

Sex differences in response to intranasal oxytocin as an adjunctive therapy for patients with severe mental illness

Article

Author: Grossman-Giron, Ariella ; Sedoff, Omer ; Maoz, Hagai ; Tzur Bitan, Dana ; Bitan, Dana Tzur ; Baruch, Noam ; Mama, Yaniv ; Nitzan, Uri

Studies investigating the potential benefits of intranasal oxytocin (INOT) as an add-on treatment for patients with severe mental illness (SMI) have yielded inconsistent results, potentially due to sex differences in response to INOT. This study explored the differential effects of INOT among male and female patients with SMI. A secondary analysis was conducted on a previously studied group of patients who participated in a double-blind, placebo-controlled trial evaluating the impact of INOT as an add-on treatment for patients with SMI. Patients treated in inpatient settings (N = 87) received twice-daily INOT (32IU) or placebo (PLC) for a period of four weeks. Sex moderated the effect of OT/PLC on the Hamilton Rating Scale for Depression (HRDS) (p < 0.001). A significant effect for sex was found in the Hopkins Symptom Checklist-short form (HSCL-11) (p = 0.04) and HRDS (p < 0.001), with females showing greater reductions in anxiety and depression symptoms and severity. This effect was not found for males. We conclude that the addition of INOT to the treatment of patients with SMI in an inpatient setting was beneficial for female patients, particularly reducing depressive symptoms, but not for male patients. Future studies should aim to identify patients who are more likely to benefit from INOT administration.

100 Deals associated with Levocarnitine propionate hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04713	-	A16AA01	DB15980

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Peripheral Vascular Diseases	Italy	-	01 Jan 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colitis, Ulcerative	Phase 3	European Union	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
Kidney Diseases	Phase 3	European Union	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
Peripheral arterial occlusive disease	Phase 3	United States	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
Peripheral Arterial Disease	Discovery	China	Lee's Pharmaceutical Holdings Ltd.	01 May 2008
Intermittent Claudication	Discovery	United States	Alfasigma SpA	01 Apr 2006
Peripheral Vascular Diseases	Discovery	United States	Alfasigma SpA	01 Apr 2006
Peripheral arterial occlusive disease	Discovery	United States	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2022	Not Applicable	Head and Neck Neoplasms	150	L-carnitine 500mg	(qnwfsoavph) = bxzbjnsjir lnxyxndzwm (tbewqewmro )	-	10 Sep 2022
				L-carnitine (Control)	(qnwfsoavph) = zlfqidvple lnxyxndzwm (tbewqewmro )
NCT01107730 (CTgov)	Phase 3	Atrial Fibrillation	33	L-carnitine (L-Carnitine)	ztktknqrsn(zyieixcany) = zcwxuwchva inispvhcvi (dazxrrrayy, ueekaojozk - axpxzyohdv) View more	-	13 May 2015
				Vitamin C (Vitamin C)	ztktknqrsn(zyieixcany) = daglicyclf inispvhcvi (dazxrrrayy, ftsqeqzxsm - qmnvaearjg) View more
NCT00399919 (Pubmed \| J Cardiopulm Rehabil Prev)	Phase 3	Peripheral Arterial Disease	69	Propionyl-L-carnitine	kkkiktxxvl(mkuavlknbl) = zyhrghwren neoxrwvcvw (rwcprwvlhb )	-	01 Mar 2011
				Placebo	kkkiktxxvl(mkuavlknbl) = iqiihsfkan neoxrwvcvw (rwcprwvlhb )